Literature DB >> 19158098

IGHMBP2 is a ribosome-associated helicase inactive in the neuromuscular disorder distal SMA type 1 (DSMA1).

Ulf-Peter Guenther1, Lusy Handoko, Bernhard Laggerbauer, Sibylle Jablonka, Ashwin Chari, Mona Alzheimer, Jürgen Ohmer, Oliver Plöttner, Niels Gehring, Albert Sickmann, Katja von Au, Markus Schuelke, Utz Fischer.   

Abstract

Distal spinal muscular atrophy type 1 (DSMA1) is an autosomal recessive disease that is clinically characterized by distal limb weakness and respiratory distress. In this disease, the degeneration of alpha-motoneurons is caused by mutations in the immunoglobulin mu-binding protein 2 (IGHMBP2). This protein has been implicated in DNA replication, pre-mRNA splicing and transcription, but its precise function in all these processes has remained elusive. We have purified catalytically active recombinant IGHMBP2, which has enabled us to assess its enzymatic properties and to identify its cellular targets. Our data reveal that IGHMBP2 is an ATP-dependent 5' --> 3' helicase, which unwinds RNA and DNA duplices in vitro. Importantly, this helicase localizes predominantly to the cytoplasm of neuronal and non-neuronal cells and associates with ribosomes. DSMA1-causing amino acid substitutions in IGHMBP2 do not affect ribosome binding yet severely impair ATPase and helicase activity. We propose that IGHMBP2 is functionally linked to translation, and that mutations in its helicase domain interfere with this function in DSMA1 patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158098     DOI: 10.1093/hmg/ddp028

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  32 in total

Review 1.  SF1 and SF2 helicases: family matters.

Authors:  Margaret E Fairman-Williams; Ulf-Peter Guenther; Eckhard Jankowsky
Journal:  Curr Opin Struct Biol       Date:  2010-04-22       Impact factor: 6.809

Review 2.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

Review 3.  Inherited neuropathies: clinical overview and update.

Authors:  Christopher J Klein; Xiaohui Duan; Michael E Shy
Journal:  Muscle Nerve       Date:  2013-06-26       Impact factor: 3.217

4.  Structure and Mechanisms of SF1 DNA Helicases.

Authors:  Kevin D Raney; Alicia K Byrd; Suja Aarattuthodiyil
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

Review 5.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

6.  Selective vulnerability in neuronal populations in nmd/SMARD1 mice.

Authors:  Eric Villalón; Monir Shababi; Rachel Kline; Zachary C Lorson; Kyra M Florea; Christian L Lorson
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

Review 7.  RNA helicases at work: binding and rearranging.

Authors:  Eckhard Jankowsky
Journal:  Trends Biochem Sci       Date:  2011-01       Impact factor: 13.807

8.  Rescue of a Mouse Model of Spinal Muscular Atrophy With Respiratory Distress Type 1 by AAV9-IGHMBP2 Is Dose Dependent.

Authors:  Monir Shababi; Zhihua Feng; Eric Villalon; Christine M Sibigtroth; Erkan Y Osman; Madeline R Miller; Patricka A Williams-Simon; Abby Lombardi; Thalia H Sass; Arleigh K Atkinson; Michael L Garcia; Chien-Ping Ko; Christian L Lorson
Journal:  Mol Ther       Date:  2016-02-10       Impact factor: 11.454

9.  Biochemical and genetic evidence for a role of IGHMBP2 in the translational machinery.

Authors:  Mariàngels de Planell-Saguer; David G Schroeder; Maria Celina Rodicio; Gregory A Cox; Zissimos Mourelatos
Journal:  Hum Mol Genet       Date:  2009-03-19       Impact factor: 6.150

Review 10.  RNA processing defects associated with diseases of the motor neuron.

Authors:  Stephen J Kolb; Scott Sutton; Daniel R Schoenberg
Journal:  Muscle Nerve       Date:  2010-01       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.